ProShare Advisors LLC Increases Stake in Danaher Corporation $DHR

ProShare Advisors LLC raised its position in Danaher Corporation (NYSE:DHR) by 11.2% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 116,909 shares of the conglomerate’s stock after acquiring an additional 11,771 shares during the period. ProShare Advisors LLC’s holdings in Danaher were worth $23,094,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in DHR. PFG Advisors boosted its holdings in Danaher by 19.4% in the 2nd quarter. PFG Advisors now owns 35,488 shares of the conglomerate’s stock valued at $7,010,000 after purchasing an additional 5,774 shares in the last quarter. SFE Investment Counsel boosted its stake in shares of Danaher by 5.9% in the second quarter. SFE Investment Counsel now owns 25,145 shares of the conglomerate’s stock valued at $4,967,000 after buying an additional 1,401 shares in the last quarter. Midwest Trust Co acquired a new position in Danaher during the second quarter worth $23,453,000. Flossbach Von Storch SE raised its position in Danaher by 7.9% in the second quarter. Flossbach Von Storch SE now owns 4,228,515 shares of the conglomerate’s stock worth $835,301,000 after acquiring an additional 307,912 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in Danaher by 3.2% in the second quarter. Acadian Asset Management LLC now owns 51,051 shares of the conglomerate’s stock valued at $10,083,000 after acquiring an additional 1,596 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Up 2.2%

Shares of DHR opened at $215.80 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The stock has a market cap of $152.43 billion, a price-to-earnings ratio of 44.49, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The firm has a 50 day simple moving average of $204.36 and a 200-day simple moving average of $200.64.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. The firm had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.Danaher’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.71 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of recent analyst reports. Bank of America lowered their price target on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Guggenheim restated a “buy” rating and set a $250.00 target price on shares of Danaher in a research report on Wednesday, July 23rd. Rothschild & Co Redburn reiterated a “neutral” rating and set a $220.00 price target (down from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft upped their price target on Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Finally, Redburn Partners set a $220.00 price objective on Danaher in a research note on Wednesday, October 8th. Eighteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $243.39.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.